Multi-spanning membrane proteins are the targets of ~50% of all small-molecule drugs but only 3 therapeutic monoclonal antibodies (MAbs), due to the challenges of working with these complex proteins.
We are the industry leader in discovering antibodies against complex membrane protein targets, with a success rate of 95%. Our specialized technologies provide unprecedented access to an entire class of clinically important, yet untapped, targets.
